skip to content


Circassia launches nasal application in Europe

12 September 2017 08:01

Circassia Pharmaceuticals, a speciality pharmaceutical company focused on respiratory disease, has announced the European launch of the NIOX VERO nasal application for the screening of primary ciliary dyskinesia (PCD).

Circassia launched the application at the world's largest meeting of respiratory professionals, the European Respiratory Society (ERS) 2017 International Congress in Milan, Italy.

At 8:01am: (LON:CIR) Circassia Pharmaceuticals Plc share price was -1p at 87.5p

Story provided by

Related Company: CIR

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.